PG
NBIX icon

Pendal Group’s Neurocrine Biosciences NBIX Stock Holding History

Pendal Group’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-3,784
Closed -$322K – 547
2021
Q4 		$322K Buy
+3,784
New +$348K ﹤0.01% 492
2021
Q3 		– Sell
-3,442
Closed -$335K – 629
2021
Q2 		$335K Buy
+3,442
New +$330K ﹤0.01% 468

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Pendal Group's NBIX Position: Q1 2022 in Review

Pendal Group sold out of Neurocrine Biosciences (NBIX) in Q1 2022, closing a stake of 3,784 shares — an estimated $322K sold.

Pendal Group first reported a position in NBIX in Q2 2021 and held it in 2 quarters. The position peaked at $335K in Q2 2021. 426 funds tracked by Wall St. Rank hold NBIX as of Q1 2022.

  • Pendal Group reported no remaining Neurocrine Biosciences position as of Q1 2022 after selling out during the quarter.
  • Pendal Group sold 3,784 Neurocrine Biosciences shares in Q1 2022, an estimated $322K.
  • Pendal Group first reported a position in Neurocrine Biosciences in Q2 2021 and held it in 2 quarters.
  • Pendal Group's Neurocrine Biosciences position peaked at $335K in Q2 2021.
  • 426 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2022.

Based on Pendal Group's 13F filing for Q1 2022, filed 25 Apr 2022.